Better Health for All

Palisade Bio's entire business is devoted to developing novel therapeutics for acute and chronic gastrointestinal complications, including ulcerative colitis and Crohn's disease. Their lead product candidate, PALI-2108, is in Phase 1a/b clinical trials and has shown positive preclinical data, including reduced colitis symptoms in a mouse model.

The company's focus on treating significant diseases positions its entire portfolio as delivering exceptional health benefits. In terms of safety, Phase 1a/b clinical studies for PALI-2108 have reported no serious adverse events (SAEs) or treatment-related adverse events (TRAEs) in initial cohorts. One moderate event led to withdrawal in a multiple ascending dose study at 50 mg BID, and mild, reversible treatment-emergent adverse events (TEAEs) were limited to the highest dose (450 mg) in a single ascending dose study. The company publicly registers its clinical trials on clinicaltrials.gov (NCT06663605), indicating strong transparency in its research activities and adherence to ethical guidelines.

Fair Money & Economic Opportunity

Palisade Bio, Inc. is a biopharmaceutical company focused on developing therapeutics, not a financial institution.

As such, the company does not offer lending, deposit, or other consumer financial services. Therefore, all KPIs related to fair money and economic opportunity, such as underserved client share, pricing fairness, exploitative fee exposure, inclusion initiatives, data accessibility, fair lending compliance, wealth building outcomes, financial literacy initiatives, debt burden ratio, geographic inclusion, and product simplicity, are not applicable to its core business model. The company reported a net operating loss of $13.1 million in 2023 and a $3.5 million quarterly net loss in 2024, indicating no profits for community reinvestment.

Kind to Animals

Palisade Bio conducts extensive animal testing, including acute colitis models in mice for efficacy and toxicity assessments in dogs and monkeys for preclinical studies.

While the company utilizes some non-animal methods such as Cellular Thermal Shift Assay (CETSA) on colon tissue homogenates and ex vivo studies with human stool and blood samples, animal tests appear to be the primary approach for critical endpoints. There is no evidence of a formal animal testing policy, its scope, or enforcement. The company has conducted a microbiome study in collaboration with CosmosID, but there is no evidence of participation in broader multi-stakeholder initiatives to develop industry-wide animal-free testing standards.

No War, No Weapons

No specific, concrete data points for Palisade Bio, Inc. (PALI.US) related to the 'No War, No Weapons' value were found in the provided articles. One article explicitly states that sustainability data is unavailable for PALI.US.

The other article refers to an ESG policy from 'Palisade Investment Partners Limited', which is a different entity and therefore not applicable to PALI.US.